drugset / Trial / NCT03228043
Apatinib for Resectable Colorectal Cancer
Withdrawn
Nanchong Central Hospital
RandomizedParallel-groupTriple-blindTreatment
Summary
Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively. Language: English.
Timeline
- Start
- 2020-03-01
- Primary completion
- 2021-03-01
- Completion
- 2023-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |